Companies › Aprea Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| APR-1051 WEE1 inhibitor | WEE1 | Phase 1 | Advanced Solid Tumor | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06260514 | APR-1051 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2027 |
Cash of $38m on 2026-09-30; operating cash outflow about $13m a year; runway about 35 months at that burn, to Aug 2029
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
AstraZeneca K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.